BRIEF-Health Canada Approves Keytruda SC™, A Subcutaneous Formulation Of Pembrolizumab Across Multiple Cancer Indications
Merck & Co., Inc. -1.72% Pre
Merck & Co., Inc. MRK | 117.90 117.90 | -1.72% 0.00% Pre |
Feb 17 (Reuters) - HEALTH CANADA :
HEALTH CANADA APPROVES KEYTRUDA SC™, A SUBCUTANEOUS FORMULATION OF PEMBROLIZUMAB ACROSS MULTIPLE CANCER INDICATIONS
